$16.5m top-up propels Sutro's unnatural approach to biologics and drug conjugates
This article was originally published in Scrip
Executive Summary
Sutro Biopharma closed the second tranche of a previously announced Series C funding round, bringing in $16.5 million in new cash to finance development of next-generation antibody-drug conjugates (ADCs) and complete renovations at a manufacturing facility for the San Francisco company's cell-free biochemical protein synthesis platform.